Results 261 to 270 of about 457,473 (371)

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. [PDF]

open access: yesHemasphere, 2021
Mesa RA   +14 more
europepmc   +1 more source

JI‐CJ002 and Dabrafenib Combination Enhances Antitumor Activity in Melanoma Associated With the Downregulation of B7‐H3

open access: yesCancer Science, EarlyView.
Schematic pathway diagram illustrating the effects of JI‐CJ002 and dabrafenib on melanoma progression. The combination of JI‐CJ002 and dabrafenib is associated with reduced B7‐H3 expression and modulation of signaling pathways implicated in melanoma progression, including JAK2/STAT3, PI3K/AKT/mTOR, and Rb/E2F1.
Sang‐Eun Lee   +4 more
wiley   +1 more source

Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine Inhibitors.

open access: yesACS Medicinal Chemistry Letters, 2015
A. Hart   +19 more
semanticscholar   +1 more source

Multifunctional Role of Mitochondrial Fatty Acid Oxidation in Cancer Immunotherapy and Aging

open access: yesCancer Science, EarlyView.
Recent studies have highlighted the complex interplay between tumor immunity, aging, and inflammation. Mitochondrial FAO is a major hub of this physiological interplay. ABSTRACT Recent studies have demonstrated the intricate relationship between tumor immunity, aging, and inflammation.
Koji Kitaoka   +4 more
wiley   +1 more source

Janus Kinase 2 Inhibitor AG490 Inhibits the STAT3 Signaling Pathway by Suppressing Protein Translation of gp130 [PDF]

open access: hybrid, 2009
In Ae Seo   +6 more
openalex   +1 more source

Home - About - Disclaimer - Privacy